JP2023539525A5 - - Google Patents

Info

Publication number
JP2023539525A5
JP2023539525A5 JP2023514116A JP2023514116A JP2023539525A5 JP 2023539525 A5 JP2023539525 A5 JP 2023539525A5 JP 2023514116 A JP2023514116 A JP 2023514116A JP 2023514116 A JP2023514116 A JP 2023514116A JP 2023539525 A5 JP2023539525 A5 JP 2023539525A5
Authority
JP
Japan
Prior art keywords
days
use according
sequence
weeks
vaccine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023514116A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023539525A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2021/074314 external-priority patent/WO2022049220A2/en
Publication of JP2023539525A publication Critical patent/JP2023539525A/ja
Publication of JP2023539525A5 publication Critical patent/JP2023539525A5/ja
Pending legal-status Critical Current

Links

JP2023514116A 2020-09-02 2021-09-02 抗体療法 Pending JP2023539525A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20194018.6 2020-09-02
EP20194018 2020-09-02
PCT/EP2021/074314 WO2022049220A2 (en) 2020-09-02 2021-09-02 Antibody therapy

Publications (2)

Publication Number Publication Date
JP2023539525A JP2023539525A (ja) 2023-09-14
JP2023539525A5 true JP2023539525A5 (cg-RX-API-DMAC7.html) 2024-09-09

Family

ID=72340230

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023514116A Pending JP2023539525A (ja) 2020-09-02 2021-09-02 抗体療法

Country Status (7)

Country Link
US (1) US20230310599A1 (cg-RX-API-DMAC7.html)
EP (1) EP4208200A2 (cg-RX-API-DMAC7.html)
JP (1) JP2023539525A (cg-RX-API-DMAC7.html)
CN (1) CN116472060A (cg-RX-API-DMAC7.html)
BR (1) BR112023003868A2 (cg-RX-API-DMAC7.html)
IL (1) IL300835A (cg-RX-API-DMAC7.html)
WO (1) WO2022049220A2 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI3322727T3 (fi) 2015-07-15 2026-03-17 Genmab As Humanisoituja tai kimeerisiä CD3-vasta-aineita
KR20230008775A (ko) 2020-05-08 2023-01-16 젠맵 에이/에스 Cd3 및 cd20에 대한 이중특이적 항체
US20220313816A1 (en) * 2021-04-01 2022-10-06 Human Vaccines Project Compositions and methods for antibody-as-adjuvant vaccines and therapeutics

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
GB9203459D0 (en) 1992-02-19 1992-04-08 Scotgen Ltd Antibodies with germ-line variable regions
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
DE10043437A1 (de) 2000-09-04 2002-03-28 Horst Lindhofer Verwendung von trifunktionellen bispezifischen und trispezifischen Antikörpern zur Behandlung von malignem Aszites
US7741568B2 (en) 2005-01-13 2010-06-22 The Wiremold Company Downward facing receptacle assembly for cable raceway
KR101374454B1 (ko) 2005-03-31 2014-03-17 추가이 세이야쿠 가부시키가이샤 회합제어에 의한 폴리펩티드 제조방법
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
KR101866623B1 (ko) 2005-11-28 2018-07-04 젠맵 에이/에스 재조합 1가 항체 및 그의 제조 방법
EA015992B1 (ru) 2006-03-17 2012-01-30 Байоджен Айдек Эмэй Инк. Стабилизированное антитело и многовалентная антигенсвязывающая молекула на его основе, способы получения и использования вышеназванного стабилизированного антитела
DK1999154T3 (da) 2006-03-24 2012-12-03 Merck Patent Gmbh Fremstillede heterodimere proteindomæner
EP2158221B1 (en) 2007-06-21 2018-08-29 MacroGenics, Inc. Covalent diabodies and uses thereof
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
EP3663318A1 (en) 2008-01-07 2020-06-10 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
US8658178B2 (en) * 2008-03-19 2014-02-25 Yale University Carbon nanotube compositions and methods of use thereof
WO2010015792A1 (en) 2008-08-06 2010-02-11 Argenta Discovery Limited Nitrogen containing heterocyclic compounds useful as bifunctional modulators of m3 receptors and beta-2 receptors
JP5734201B2 (ja) 2008-12-19 2015-06-17 マクロジェニクス,インコーポレーテッド 共有結合型ダイアボディ及びその使用
US9067986B2 (en) 2009-04-27 2015-06-30 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
TWI426920B (zh) 2010-03-26 2014-02-21 Hoffmann La Roche 雙專一性、雙價抗-vegf/抗-ang-2抗體
PT2560993T (pt) 2010-04-20 2024-09-16 Genmab As Proteínas contendo anticorpo heterodimérico fc e métodos para a produção das mesmas
WO2011143545A1 (en) 2010-05-14 2011-11-17 Rinat Neuroscience Corporation Heterodimeric proteins and methods for producing and purifying them
BR112013002167A2 (pt) 2010-08-24 2016-05-31 Roche Glycart Ag anticorpo biespecífico, composição farmacêutica, uso, método de tratamento de um paciente que sofre de câncer e de um paciente que sofre de inflamação
CN103068846B9 (zh) 2010-08-24 2016-09-28 弗·哈夫曼-拉罗切有限公司 包含二硫键稳定性Fv片段的双特异性抗体
CN103429620B (zh) 2010-11-05 2018-03-06 酵活有限公司 在Fc结构域中具有突变的稳定异源二聚的抗体设计
CN102250246A (zh) 2011-06-10 2011-11-23 常州亚当生物技术有限公司 抗VEGF/PDGFRβ双特异性抗体及其应用
WO2014006217A1 (en) * 2012-07-06 2014-01-09 Genmab B.V. Dimeric protein with triple mutations
MX428954B (es) * 2013-03-15 2025-11-13 Univ Pennsylvania Vacunación mejorada contra la hormona liberadora de la hormona de crecimiento (ghrh) humana.
CN105073128A (zh) * 2013-04-03 2015-11-18 Ibc药品公司 用于诱导对疾病的免疫应答的组合疗法
KR102813816B1 (ko) 2013-07-05 2025-05-29 젠맵 에이/에스 인간화 또는 키메라 cd3 항체
US9727636B2 (en) 2013-09-30 2017-08-08 Microsoft Technology Licensing, Llc Generating excutable code from complaint and non-compliant controls
CN108602889A (zh) * 2015-12-22 2018-09-28 瑞泽恩制药公司 医治急性成淋巴细胞性白血病的双特异性抗cd20/抗cd3抗体
SG11201907867TA (en) 2017-02-28 2019-09-27 Bristol Myers Squibb Co Use of anti-ctla-4 antibodies with enhanced adcc to enhance immune response to a vaccine
KR20190123328A (ko) * 2017-03-09 2019-10-31 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 암 백신
AU2019274654B2 (en) * 2018-05-23 2023-07-20 Pfizer Inc. Antibodies specific for CD3 and uses thereof
MX2020012598A (es) * 2018-05-24 2021-05-27 Janssen Biotech Inc Agentes aglutinantes del psma y usos de estos.
BR112020023508A2 (pt) * 2018-05-24 2021-03-30 Janssen Biotech, Inc. Anticorpos anti-cd3 e usos dos mesmos
CN112513081A (zh) * 2018-06-14 2021-03-16 生物蛋白有限公司 多重特异性抗体构建体
TW202504917A (zh) * 2018-06-21 2025-02-01 美商再生元醫藥公司 用雙特異性抗CD3xMUC16抗體及抗PD-1抗體治療癌症之方法
BR112021008486A2 (pt) * 2018-11-01 2021-10-26 Shandong New Time Pharmaceutical Co., Ltd Anticorpo biespecífico e seu uso

Similar Documents

Publication Publication Date Title
CA2422002C (en) Vaccine
US20170080064A1 (en) Methods and compositions for increasing a t-effector cell to regulatory t cell ratio
JP2021531345A (ja) 腫瘍ワクチン接種に用いるための組合せ製品
Jemon et al. An enhanced heterologous virus-like particle for human papillomavirus type 16 tumour immunotherapy
US20230310599A1 (en) Antibody therapy
US12358996B2 (en) Fusion proteins for immunotherapy against cancer and infectious diseases
KR102728174B1 (ko) 백신 보조제로서 gm3 강글리오시드의 합성 변이체를 포함하는 나노입자
US20240409608A1 (en) Combination therapies against cancer and infectious diseases
Sharif et al. Bioengineered ClearColi™-derived outer membrane vesicles displaying CT26 neoepitopes as potent vaccine adjuvants against colon carcinoma in a preventive mouse model
CA3107263A1 (en) Nasal vaccine that induces cell-mediated immunity
CN121405821B (zh) 一种融合蛋白及在制备治疗或预防乙肝病毒产品中的应用
HK1136785A (en) Vaccine against streptococcus pneumoniae